Search
3,4-Methylenedioxy-N-isopropylamphetamine
go.drugbank.com/drugs/DB06112ExperimentalMDI-P is also a potential therapeutic agent for the treatment of the symptoms of cystic fibrosis ("CF"). … MDI-P has demonstrated potent anti-HIV activity. MDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS).
Synonyms: MDI-P, 3,4-Methylenedioxy-N-isopropylamphetamineFlucloxacillin
go.drugbank.com/drugs/DB00301ApprovedInvestigationalWithdrawnAntibiotic analog of cloxacillin.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersSynonyms: (2S,5R,6R)-6-({[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-(2-Chloro-6-fluorophenyl)-5-methyl-4-isoxazolylpenicillinDTS-201
go.drugbank.com/drugs/DB06071ExperimentalDTS-201 is a prodrug of doxorubicin, a widely used anti-cancer drug that Diatos intends to develop for the treatment of various solid tumors. It is activated in the tumor environment. … DTS-201 may be suitable for the treatment of many types of solid tumors, including tumors sensitive to doxorubicin and potentially other tumors which are not currently treated with doxorubicin but which
Idoxuridine
go.drugbank.com/drugs/DB00249ApprovedWithdrawnThe drug is used as an antiviral agent.
Categories: Heterocyclic Compounds, 1-RingSynonyms: 1-(2-Deoxy-beta-D-ribofuranosyl)-5-iodouracil, 1-beta-D-2'-Deoxyribofuranosyl-5-iodouracilNOX-100
go.drugbank.com/drugs/DB05799InvestigationalNOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.
GFT14
go.drugbank.com/drugs/DB05061ExperimentalGFT14 is destined to improve the condition of patients at risk from cardiovascular disease by a simultaneous and favorable action on the plasmatic lipids (rise of HDL- cholesterol et lowering of triglycerides … GFT14 aims to target mixed dyslipidemia of type IIb (high levels of triglycerides and LDL-C) as one of the major indications of cardiometabolic disease.
SP1049C
go.drugbank.com/drugs/DB04978Experimental[A260416] It is designed to overcome drug resistance in a number of cancers. It has successfully completed Phase 1 trials. Phase 2 results are currently under final review. … Preliminary data, in its first clinically tested indication, shows that SP1049C is active in Stage IV non-resectable adenocarcinoma of the esophagus.
Categories: Compounds used in a research, industrial, or household settingSynonyms: doxorubicin with pluronics F-127 and L-61, Doxorubicin HCl with pluronic L-61 and pluronic F-127gamma-Aminobutyric acid
go.drugbank.com/drugs/DB02530ApprovedInvestigationalThe most common inhibitory neurotransmitter in the central nervous system.
Synonyms: γ-amino-n-butyric acid, 4-aminobutanoic acidMixtures: Therabenzaprine-90-5UCB7362
go.drugbank.com/drugs/DB17096ExperimentalUCB7362 is an orally active plasmepsin X (PMX) inhibitor currently investigated for the treatment of malaria. … [A254232] UCB7362 is estimated to achieve a significant reduction in asexual blood-stage parasites.
PRO 2000
go.drugbank.com/drugs/DB05385InvestigationalThis medicine does not cure HIV infection or AIDS and is being studied to reduce the risk of passing the virus to other people. … PRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials.
Categories: Compounds used in a research, industrial, or household settingSynonyms: Naphthalene 2-sulfonate polymer